NCT05187182 2026-03-18
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Washington University School of Medicine
Phase 1 Recruiting
Clinical Trials
16 trialsNCT06346197 2026-03-02
CIME
Centre Leon Berard
Phase 3 Recruiting
NCT05802056 2025-12-19
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
Mayo Clinic
Phase 1 Recruiting
NCT04157985 2025-12-11
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Phase 3 Completed
NCT06253611 2025-09-22
BIG
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Recruiting
NCT07098104 2025-08-01
A Benefit Population Atlas of nICT Versus nCT for LAGC
Jiangsu Cancer Institute & Hospital
Completed
NCT03044613 2025-03-06
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT03453164 2024-09-19
Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)
Fukushima Medical University
Phase 1/2 Completed
NCT03172416 2024-05-29
PIPAC
National University Hospital, Singapore
Phase 1 Active not recruiting
NCT04062656 2024-03-12
IMAGINE
University Hospital, Essen
Phase 2 Unknown
NCT05859477 2024-01-02
NIVOFGFR2
Kidney Cancer Research Bureau
Phase 2 Unknown
NCT03995017 2023-02-01
RiME
University of Kansas Medical Center
Phase 1/2 Unknown
NCT03409848 2022-05-18
INTEGA
AIO-Studien-gGmbH
Phase 2 Completed
NCT04503967 2020-08-07
OASIS
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT02946671 2020-03-06
Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients
Osaka University
Phase 1 Completed
NCT03784040 2019-04-08
da VINci
National University Hospital, Singapore
Phase 1 Unknown